Amit Khot (A Khot)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 12

Top Venues

Leukemia & lymphoma

Blood advances

Blood

Bone marrow transplantation

Peter MacCallum Cancer Centre and Royal Melbourne Hospital

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Peter MacCallum Cancer Centre and Royal Melbourne Hospital

Australia

Clinical Haematologist and BMT Physician :: Clinical Haematology

Publications

Marco Herling, Claire Dearden, Francesco Zaja, Dima El-Sharkawi, Wei Ding, Mar Bellido, Amit Khot, Lidwine Tick, Eric Jacobsen, Toby Andrew Eyre, Damien Roosweil, Tapan Kadia, Elisa Lucchini, Natali Pflug, Matthew S Davids, German Pena, Nabanita Mukherjee, Mohamed Badawi, Tamas Vizkelety, Philipp Bernhard Staber
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study. Blood advances 8 (4) (2024)
Marco Herling, Claire Dearden, Francesco Zaja, Dima El-Sharkawi, Wei Ding, Mar Bellido, Amit Khot, Lidwine Tick, Eric Jacobsen, Toby Andrew Eyre, Damien Roosweil, Tapan Kadia, Elisa Lucchini, Natali Pflug, Matthew S Davids, German Pena, Nabanita Mukherjee, Mohamed Badawi, Tamas Vizkelety, Philipp Bernhard Staber
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study. Blood advances 8 (4) (2024)
Marco Herling, Claire Dearden, Francesco Zaja, Dima El-Sharkawi, Wei Ding, Mar Bellido, Amit Khot, Lidwine W Tick, Eric Jacobsen, Toby Andrew Eyre, Damien Roosweil, Tapan M Kadia, Elisa Lucchini, Natali Pflug, Matthew S Davids, German Pena, Nabanita Mukherjee, Mohamed Badawi, Tamas Vizkelety, Philipp Bernhard Staber
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study. Blood advances (2024)
S Robinson, S Wu, Stephen Lade, C S Tam, E Wong, Amit Khot, P Blombery
CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma. Leukemia & lymphoma (2024)
Adrian G Minson, Nada Hamad, Chan Yoon Y Cheah, Constantine S Tam, Piers Blombery, David A Westerman, David S Ritchie, Huw Morgan, Nicholas Holzwart, Stephen Lade, Mary Ann Anderson, Amit Khot, John Francis Seymour, Molly Robertson, Imogen Caldwell, Georgina L Ryland, Javad Saghebi, Zahra Sabahi, Jing Xie, Rachel M Koldej, Michael J Dickinson
CAR T-cells and Time-Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: Phase II TARMAC Study. Blood (2023)
Amit Khot
Del(1p32): prime time in (ultra) high-risk myeloma. Blood 141 (11) (2023)
Melissa Ng Liet Hing, Amit Khot
Lenalidomide maintenance in Myeloma - a goldilocks problem? Leukemia & lymphoma (2023)
Thomas E Lew, Edward Robert Scheffer Cliff, Michael J Dickinson, Constantine S Tam, John Francis Seymour, Piers A Blombery, Ashish Bajel, David S Ritchie, Amit Khot
Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53 -mutated disease. Leukemia & lymphoma (2023)
Amit Khot
Del(1p32): prime time in (ultra) high-risk myeloma. Blood 141 (11) (2023)
Leisa R Watson, Thomas E Lew, Lucy Claire Fox, Amit Khot, Carrie van der Weyden
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma. Leukemia & lymphoma (2022)
Jessica Elliott, Shalini Ahlawat, Henry Miles Prince, Glen Kennedy, Jillian Wells, Gillian Huang, Jenny Collins, Peter Bardy, Carrie Van Der Weyden, David Ritchie, Amit Khot
Long-term outcomes for allogeneic bone marrow transplantation in Sezary syndrome and mycosis fungoides. Bone marrow transplantation 57 (11) (2022)
Amit Khot, Natalie Brajanovski, Donald P Cameron, Nadine Hein, Kylee H Maclachlan, Elaine Sanij, John Lim, John Soong, Emma Link, Piers Blombery, Ella R Thompson, Andrew Fellowes, Karen E Sheppard, Grant A McArthur, Richard B Pearson, Ross D Hannan, Gretchen Poortinga, Simon James Harrison
First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. Cancer discovery 9 (8) (2019)

Amit Khot.css-eqlu8i{font-size:small;padding-left:4px;} (A Khot)

Publication Activity (10 Years)

Top Topics

Top Venues

Amit Khot (A Khot)